Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
- K. P. Garnock-jones, G. Keating
- Medicine
- Paediatric drugs
- 2009
Atomoxetine (Strattera(R)) is a selective norepinephrine (noradrenaline) reuptake inhibitor that is not classified as a stimulant, and is indicated for use in patients with attention-deficit… Expand
Panobinostat: First Global Approval
- K. P. Garnock-jones
- Medicine
- Drugs
- 3 April 2015
Novartis has developed oral and intravenous formulations of panobinostat (Farydak®), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer. HDACs have important roles in maintaining… Expand
Loxoprofen: A Review in Pain and Inflammation
- S. Greig, K. P. Garnock-jones
- Medicine
- Clinical Drug Investigation
- 21 July 2016
Loxoprofen (Loxonin®, Loxonin® Pap, Loxonin® Tape) is a prodrug-type NSAID that is available in several formulations, including 60 mg tablets, 100 mg hydrogel patches and 50 or 100 mg tape. In active… Expand
Ripasudil: First Global Approval
- K. P. Garnock-jones
- Medicine
- Drugs
- 21 November 2014
Ripasudil hydrochloride hydrate (Glanatec® ophthalmic solution 0.4 %; hereafter referred to as ripasudil) is a small-molecule, Rho-associated kinase inhibitor developed by Kowa Company, Ltd. for the… Expand
Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.
- K. P. Garnock-jones
- Medicine
- Drugs
- 2012
Supraventricular tachyarrhythmia (including atrial fibrillation), hypertension and tachycardia in the perioperative setting, and acute ischaemic heart disease are generally agreed to require rapid… Expand
Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure
- K. P. Garnock-jones
- Medicine
- Drugs
- 14 March 2013
Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate that is specifically targeted against CD30-positive cancer cells such as those in Hodgkin lymphoma or systemic anaplastic large cell… Expand
Brexpiprazole: A Review in Schizophrenia
- K. P. Garnock-jones
- Medicine
- CNS Drugs
- 29 March 2016
Oral brexpiprazole (Rexulti®) is a partial dopamine D2 agonist, which also has activity at several other receptors. This article reviews the pharmacological properties of brexpiprazole and its… Expand
Secukinumab: A Review in Moderate to Severe Plaque Psoriasis
- K. P. Garnock-jones
- Medicine
- American Journal of Clinical Dermatology
- 23 July 2015
Secukinumab (Cosentyx™) is a fully human monoclonal immunoglobulin G1κ antibody targeting human interleukin-17A, an important cytokine in the pathogenesis of psoriasis. Secukinumab, as well as being… Expand
Oromucosal Midazolam: A Guide to Its Use in Paediatric Patients with Prolonged Acute Convulsive Seizures
- L. Scott, K. Lyseng-Williamson, K. P. Garnock-jones
- Medicine
- CNS Drugs
- 13 December 2012
Oromucosal midazolam (Buccolam™), a benzodiazepine, is approved in the EU for the treatment of paediatric patients (aged 3 months to <18 years) with acute, prolonged, convulsive seizures. In clinical… Expand
Vortioxetine: A Review of Its Use in Major Depressive Disorder
- K. P. Garnock-jones
- Psychology, Medicine
- CNS Drugs
- 22 August 2014
Vortioxetine (Brintellix®) is a serotonin (5-HT) transporter inhibitor that also acts on several 5-HT receptors, such as the 5-HT3 and 5-HT1A receptors. It is approved in the US and the EU for the… Expand